Drug profile · INN
trifluridine
LONSURF
trifluridine (LONSURF) is a dna inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
FDA: approved EMA: approved Antineoplastic and immunomodulating agents (L01) L01BC59
US status approved
Patents linked 0
Pipeline programs 15
News articles 0
Drug details — trifluridine
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 15
- Data quality
- 0.84
Quick answer
trifluridine (LONSURF) is a dna inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
INN trifluridine
Brand LONSURF
Mechanism DNA inhibitor
Target DNA
Therapeutic class Antineoplastic and immunomodulating agents (L01)
Route OPHTHALMIC
Formulation SOLUTION/DROPS
ATC code L01BC59
Mechanism of action
DNA inhibitor
Primary target: DNA
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is trifluridine?
trifluridine (LONSURF) is a dna inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for trifluridine?
LONSURF is a marketed brand name for trifluridine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of trifluridine?
trifluridine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.